Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 96

Results For "NCEs"

2168 News Found

Solara Active Pharma elevates Arun Kumar Baskaran to the post of CFO
People | March 09, 2024

Solara Active Pharma elevates Arun Kumar Baskaran to the post of CFO

Arun is currently working as Vice President (Strategy) in Solara leading Business finance & Strategy function


Biomanufacturing and Bio-foundry will drive India’s future bioeconomy: Dr. Jitendra Singh
Biotech | March 07, 2024

Biomanufacturing and Bio-foundry will drive India’s future bioeconomy: Dr. Jitendra Singh

India has reached to nearly 6,000 bio-startups from 50 in the past 10 years


Sakar's oncology unit receives EU GMP approval
Drug Approval | March 07, 2024

Sakar's oncology unit receives EU GMP approval

The WHO GMP approved vertically integrated ONCOLOGY unit of SAKAR has been selling products nationally since few quarters


Briefs: Zydus, Advanced Enzyme Technologies, Link Pharma Chem and ANVISA
News | March 07, 2024

Briefs: Zydus, Advanced Enzyme Technologies, Link Pharma Chem and ANVISA

ANVISA issues CGMP to Concord Biotech’s Unit I


KIMS Hospitals to acquire land on 99-year lease to set up new hospital at Thane
Healthcare | March 05, 2024

KIMS Hospitals to acquire land on 99-year lease to set up new hospital at Thane

The proposed hospital will have a bed capacity of 300 beds and the investment in the project is expected to be around Rs. 500 crore


Briefs: SMS Pharmaceuticals and Vimta Labs
News | March 03, 2024

Briefs: SMS Pharmaceuticals and Vimta Labs

EDQM conducts GMP inspection of SMS Pharmaceuticals’ API facility


Cipla incorporates JV company in USA
News | March 02, 2024

Cipla incorporates JV company in USA

Cipla completes transfer of Generics Business Undertaking


Asahi Kasei offers pharmaceutical excipient Ceolus with nitrite concentration of 0.1 ppm or less
News | February 29, 2024

Asahi Kasei offers pharmaceutical excipient Ceolus with nitrite concentration of 0.1 ppm or less

Contributing to lower risk of potentially carcinogenic nitrosamine impurities in pharmaceuticals